Perceptive Advisors
Perceptive Advisors is a privately owned hedge fund sponsor that finances the public equity markets across the globe.
Business Model:
Revenue: $13.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Perceptive Advisors Information
Geographic Data
Address: 499 Park Ave
City: New York
State: NY
Zip: 10022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Linkedin
Crunchbase
Metrics
2,160,524Website Global Rank
9,065Website Monthly Traffic
Twitter Followers
Description
Perceptive Advisors, LLC is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while making its investments. The firm typically invests in biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York, New York.
Contact Phone:
+16462055340
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2019 | Vyome Therapeutics | Series D | 22M |
| 7/2020 | Genome Medical | Series B | 0 |
| 7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
| 2/2018 | Partner Therapeutics | Series A | 60M |
| 8/2020 | ReViral | Series C | 0 |
| 11/2020 | Adagio Medical | Series E | 0 |
| 7/2015 | Outlook Therapeutics | Venture Round | 31M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 4/2022 | Surf Bio | Seed | 16M |
| 12/2020 | Solid Biosciences | Post-IPO Equity | 0 |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 12/2005 | EUSA Pharma | Venture Round | 0 |
| 9/2021 | SomaLogic | Post-IPO Equity | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 40M |
| 4/2020 | COMPASS Pathways | Series B | 0 |
| 6/2015 | Alliqua BioMedical | Post-IPO Debt | 15.5M |
| 2/2022 | Beta Bionics | Series C | 0 |
| 7/2016 | Ardelyx | Post-IPO Equity | 0 |
| 9/2020 | Willow | Series C | 0 |
| 9/2021 | Emulate | Series E | 82M |
| 9/2014 | Affimed | Debt Financing | 14M |
| 2/2022 | Omada Health | Series E | 0 |
| 5/2017 | Home Dialysis Plus | Series C | 76.5M |
| 9/2018 | Lyra Therapeutics | Series B | 0 |
| 6/2020 | C4 Therapeutics | Series B | 150M |
| 4/2021 | Forge Biologics | Series B | 120M |
| 7/2019 | Frequency Therapeutics | Series C | 0 |
| 5/2016 | AVEO Oncology | Post-IPO Equity | 17M |
| 12/2015 | Clearside Biomedical | Series C | 20M |
| 10/2021 | Honor | Debt Financing | 300M |
| 9/2021 | Hancock Jaffe Laboratories | Post-IPO Equity | 20M |
| 1/2016 | Arno Therapeutics | Post-IPO Equity | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 7/2018 | Alector | Series E | 133M |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 8/2016 | Arno Therapeutics | Post-IPO Equity | 8M |
| 3/2015 | Minerva Neuroscience | Post-IPO Equity | 0 |
| 10/2021 | Science 37 | Post-IPO Equity | 0 |
| 1/2022 | Orchestra BioMed | Series D | 0 |
| 12/2019 | Quellis Biosciences | Series A | 0 |
| 3/2020 | immatics biotechnologies | Post-IPO Equity | 0 |
| 7/2014 | Virobay | Series B | 8M |
| 10/2022 | immatics biotechnologies | Post-IPO Equity | 0 |
| 7/2019 | Neptune Wellness Solutions | Post-IPO Equity | 41.4M |
| 9/2021 | A-Alpha Bio | Series A | 20M |
| 6/2019 | PanTheryx | Venture Round | 50M |
| 5/2017 | Xontogeny | Series A | 15M |
| 2/2020 | Agile Therapeutics | Post-IPO Debt | 20M |
| 3/2015 | Champions Oncology | Post-IPO Equity | 14M |
| 1/2022 | AvengeBio | Series A | 0 |
| 12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 5/2019 | ArcherDX | Series B | 60M |
| 11/2015 | Solid Biosciences | Series B | 42.5M |
| 6/2021 | PROCEPT BioRobotics | Series G | 0 |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
| 4/2020 | Dynacure | Series C | 54.2M |
| 9/2018 | Vapotherm | Series D | 0 |
| 12/2019 | ArcherDX | Series C | 0 |
| 9/2020 | Zymergen | Series D | 300M |
| 2/2018 | PROCEPT BioRobotics | Series E | 0 |
| 11/2020 | Prometheus Biosciences | Equity | 130M |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 1/2021 | Earli | Series A | 40M |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 5/2017 | Outset Medical | Series C | 0 |
| 1/2021 | Impulse Dynamics | Series D | 60M |
| 4/2019 | Fusion Pharmaceuticals | Series B | 0 |
| 11/2017 | Counsyl | Equity | 80M |
| 10/2021 | Twin Health | Series C | 155M |
| 3/2021 | Pyxis Oncology | Series B | 152M |
| 6/2020 | DNAnexus | Series G | 0 |
| 6/2020 | Fulcrum Therapeutics | Post-IPO Equity | 0 |
| 5/2020 | Nautilus Biotechnology | Series B | 76M |
| 5/2021 | Cue | Venture Round | 235M |
| 3/2019 | Saama | Venture Round | 40M |
| 6/2016 | VitalConnect | Series B | 18M |
| 4/2019 | Kindbody | Series A | 15M |
| 10/2020 | LianBio | Series A | 0 |
| 7/2018 | Athenex | Post-IPO Equity | 50M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 7/2021 | Sema4 | Post-IPO Equity | 350M |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 12/2019 | Black Diamond Therapeutics | Series C | 0 |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 12/2016 | VBI Vaccines | Post-IPO Equity | 10.6M |
| 1/2020 | Sonendo | Venture Round | 85M |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 12/2016 | VBI Vaccines | Post-IPO Debt | 13M |
| 1/2019 | Black Diamond Therapeutics | Series B | 85M |
| 1/2021 | Clover Health | Post-IPO Equity | 400M |
| 4/2017 | Singulex | Debt Financing | 50M |
| 5/2018 | Rain Therapeutics | Series A | 18.4M |
| 1/2018 | AEGEA Medical | Series D | 0 |
| 6/2020 | C4 Therapeutics | Debt Financing | 20M |
| 5/2021 | NiKang Therapeutics | Series C | 200M |
| 8/2019 | Landos Biopharma | Series B | 60M |
| 9/2022 | InSightec | Debt Financing | 100M |
| 8/2020 | Freenome | Series C | 270M |
| 8/2016 | Vyome Therapeutics | Series C | 14M |
| 11/2015 | Celladon | Post-IPO Equity | 39.5M |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 8/2018 | Outset Medical | Series D | 0 |
| 8/2021 | Bridge to Life | Venture Round | 56M |
| 9/2017 | Landos Biopharma | Series A | 10M |
| 5/2020 | Omada Health | Venture Round | 57M |
| 2/2019 | ADMA Biologics | Post-IPO Debt | 72.5M |
| 1/2020 | Cerebral Therapeutics | Series B | 35M |
| 9/2022 | SpringWorks Therapeutics | Post-IPO Equity | 225M |
| 10/2014 | Zynerba Pharmaceuticals | Venture Round | 13M |
| 9/2020 | Rain Therapeutics | Series B | 63M |
| 3/2021 | Scribe Therapeutics | Series B | 100M |
| 7/2020 | Pear Therapeutics | Debt Financing | 50M |
| 10/2013 | Arno Therapeutics | Post-IPO Equity | 0 |
| 1/2018 | Vitruvias Therapeutics | Series A | 11.5M |
| 6/2015 | Outset Medical | Debt Financing | 45M |
| 12/2021 | Freenome | Series D | 300M |
| 8/2018 | ReViral | Series B | 0 |
| 11/2021 | Sermonix | Series A | 40M |
| 9/2016 | Establishment Labs | Debt Financing | 15M |
| 7/2016 | VBI Vaccines | Post-IPO Equity | 0 |
| 5/2019 | Athenex | Post-IPO Equity | 100M |
| 9/2015 | Outlook Therapeutics | Venture Round | - |
| 4/2018 | Kodiak Sciences | Convertible Note | 33M |
| 7/2019 | Kronos Bio | Series A | 105M |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 3/2022 | VivoSense | Series A | 0 |
| 1/2021 | Affinivax | Series C | 226M |
| 12/2016 | Motus GI | Venture Round | 0 |
| 6/2020 | AsclepiX Therapeutics | Series A | 35M |
| 7/2019 | Foamix | Post-IPO Debt | 64M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 11/2022 | Biodesix | Post-IPO Debt | 50M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 8/2017 | Molecular Templates | Post-IPO Equity | 60M |
| 1/2021 | DarioHealth | Post-IPO Equity | 70M |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 12/2016 | Vensun Pharmaceuticals | Series C | 22.5M |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 7/2020 | Kindbody | Series B | 0 |
| 12/2020 | Neuron23 | Series B | 80M |
| 5/2020 | Atea | Series D | 215M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
| 10/2020 | AavantiBio | Series A | 0 |
| 1/2020 | Lyra Therapeutics | Series C | 0 |
| 7/2020 | Forge Biologics | Series A | 40M |
| 5/2021 | Juno Diagnostics | Series A | 25M |
| 5/2007 | Spectrum Pharmaceuticals | Post-IPO Equity | 0 |
| 2/2022 | Synthego | Series E | 0 |
| 2/2022 | Endeavor BioMedicines | Series B | 101M |
| 3/2019 | Orchestra BioMed | Series B | 34M |
| 12/2022 | Apogee Therapeutics | Series B | 0 |
| 10/2016 | True North Therapeutics | Series D | 45M |
| 2/2021 | Nuvation Bio | Post-IPO Equity | 502M |
| 3/2022 | DNAnexus | Series H | 200M |
| 7/2019 | Beta Bionics | Series B | 63M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 10/2014 | Invitae | Series F | 0 |
| 11/2015 | Vapotherm | Series C | 0 |
| 4/2019 | SpringWorks Therapeutics | Series B | 125M |
| 8/2020 | Kronos Bio | Private Equity Round | 155M |
| 7/2019 | Freenome | Series B | 160M |
| 3/2022 | Neuron23 | Series C | 0 |
| 11/2020 | Achilles Therapeutics | Series C | 69.8M |
| 7/2021 | Point Biopharma | Post-IPO Equity | 0 |
| 9/2022 | Solid Biosciences | Post-IPO Equity | 75M |
| 4/2021 | Icosavax | Series B | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 3/2017 | Solid Biosciences | Series C | 0 |
| 8/2020 | Taysha Gene Therapies | Series B | 0 |
| 5/2021 | Affinia Therapeutics | Series B | 0 |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 4/2014 | Otonomy | Series D | 49M |
| 5/2023 | OnKure Therapeutics | Series C | 0 |
| 8/2021 | Genome Medical | Series C | 0 |
| 6/2019 | Genome Medical | Series B | 23M |
| 9/2019 | Achilles Therapeutics | Series B | 120.9M |
| 2/2021 | Pipeline Therapeutics | Series C | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2020 | Athira Pharma | Series B | 85M |
| 5/2023 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 12/2015 | True North Therapeutics | Series C | 40M |
| 6/2021 | Kindbody | Series C | 0 |
| 5/2019 | Confo Therapeutics | Series A | 33.6M |
| 6/2021 | Nautilus Biotechnology | Post-IPO Equity | 0 |
| 5/2017 | Vapotherm | Series D | 0 |
| 11/2014 | Blueprint Medicines | Series C | 50M |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 3/2021 | OnKure | Series B | 56.6M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 1/2021 | MIVI Neuroscience | Series B | 35M |
| 3/2021 | Crossover Health | Series D | 0 |
| 9/2021 | HilleVax | Equity | 135M |
| 8/2019 | Oncorus | Series B | 0 |
| 6/2015 | CytomX Therapeutics | Series D | 70M |
| 3/2021 | Graphite Bio | Series B | 150.7M |
| 6/2021 | RayzeBio | Series C | 108M |
| 12/2021 | Hyperfine | Post-IPO Equity | 0 |
| 1/2016 | Zymeworks | Series A | 0 |
| 12/2018 | Relay Therapeutics | Series C | 0 |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 3/2010 | Sevion Therapeutics | Post-IPO Equity | 0 |
| 9/2018 | Allogene | Convertible Note | 0 |
| 11/2019 | Avidity Biosciences | Series C | 0 |
| 4/2021 | Renovia | Series C | 0 |
| 8/2022 | MeiraGTx | Post-IPO Debt | 75M |
| 1/2021 | IsoPlexis | Series D | 85M |
| 6/2020 | CereVasc | Series A | 44M |
| 8/2020 | Metabolon | Venture Round | 72M |
| 1/2021 | IsoPlexis | Debt Financing | 50M |
| 3/2018 | Molecular Templates | Post-IPO Debt | 10M |
| 6/2016 | Corbus Pharmaceuticals | Post-IPO Equity | 14.8M |
| 3/2020 | Zucara Therapeutics | Series A | 21M |
| 3/2021 | Absci | Venture Round | 0 |
| 11/2018 | Medicrea | Post-IPO Debt | 30M |
| 8/2016 | Aquestive Therapeutics | Debt Financing | 50M |
| 5/2015 | REGENXBIO | Series D | 0 |
| 8/2018 | Renovia | Series B | 32.3M |
| 7/2019 | AgaMatrix | Debt Financing | 56M |
| 8/2017 | Dova Pharmaceuticals | Post-IPO Equity | - |
| 5/2017 | Synlogic | Series C | 42M |
| 8/2022 | MeiraGTx | Post-IPO Debt | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 0 |
| 4/2022 | Surf Bio | Seed Round | 0 |
| 4/2022 | Lyra Therapeutics | Post-IPO Equity | 0 |
| 3/2022 | VivoSense | Series A | 0 |
| 3/2022 | Neuron23 | Series C | 0 |
| 3/2022 | DNAnexus | Series H | 0 |
| 2/2022 | Omada Health | Series E | 0 |
| 2/2022 | Synthego | Series E | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
